In summary, using achemoresistance-associated metastasis experimental model and in vivo as well as in vitro functional and molecular assays, in combination with extensive clinical correlation analyses, our study provides a basis for developing strategies to abrogate the β-catenin and TGF-β together by antagonizing one molecule in NSCLC so as to simultaneously target chemoresistance and metastasis. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.